CheckMate-032 is a basket phase I/II study, evaluating the activity of nivolumab as monotherapy at a dose of 3 mg/kg or in combination with ipilimumab, a CTLA-4 inhibitor, at doses of nivolumab 1 mg/kg + ipilimumab 3 mg/kg (N1/I3) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg (N3/I1), in several malignancies including refractory ES-SCLC. The gene discussed is CTLA4; the disease is small cell lung carcinoma.